# Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)

> **NCT02474407** · PHASE2 · TERMINATED · sponsor: **Acorda Therapeutics** · enrollment: 78 (actual)

## Conditions studied

- Refractory Epilepsy

## Interventions

- **DRUG:** diazepam nasal spray
- **DRUG:** diazepam rectal gel

## Key facts

- **NCT ID:** NCT02474407
- **Lead sponsor:** Acorda Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06
- **Primary completion:** 2016-05
- **Final completion:** 2016-07
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2018-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02474407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02474407, "Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02474407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*